Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration.

[1]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2016, European heart journal.

[2]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention , 2016, Atherosclerosis.

[3]  J. Danesh,et al.  Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. , 2016, Journal of the American College of Cardiology.

[4]  G. Watts,et al.  Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. , 2016, European heart journal.

[5]  K. Retterstøl,et al.  Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death. , 2016, European heart journal.

[6]  M. M. Rahman,et al.  Worldwide trends in diabetes since 1980 : pooled analysis of 751 population-based measurement studies with over 4 . 4 million participants , 2016 .

[7]  G. Watts,et al.  Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. , 2016, Journal of the American College of Cardiology.

[8]  J. Danesh,et al.  Diagnostic Yield of Sequencing Familial Hypercholesterolemia Genes in Patients with Severe Hypercholesterolemia. , 2016 .

[9]  J. Kastelein,et al.  Statin Initiation During Childhood in Patients With Familial Hypercholesterolemia: Consequences for Cardiovascular Risk. , 2016, Journal of the American College of Cardiology.

[10]  A. Philippakis,et al.  Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape , 2015, Journal of the American Heart Association.

[11]  Ž. Reiner.  Management of patients with familial hypercholesterolaemia , 2015, Nature Reviews Cardiology.

[12]  J. Car,et al.  Familial hypercholesterolaemia: a global call to arms , 2015 .

[13]  J. Borén,et al.  Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment , 2015, European heart journal.

[14]  E. Sijbrands,et al.  Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. , 2015, European heart journal.

[15]  Lawrence A Leiter,et al.  Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.

[16]  David M. Herrington,et al.  Multiple rare alleles at LDLR and APOA5 confer risk for early-onset myocardial infarction , 2014, Nature.

[17]  J. Borén,et al.  [Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. , 2015, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[18]  P. Iversen,et al.  Mortality Among Patients With Familial Hypercholesterolemia: A Registry‐Based Study in Norway, 1992–2010 , 2014, Journal of the American Heart Association.

[19]  J. Ordovás,et al.  Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. , 2014, Journal of the American College of Cardiology.

[20]  J. Gallacher,et al.  Glycated hemoglobin measurement and prediction of cardiovascular disease. , 2014, JAMA.

[21]  S. Yamashita,et al.  Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. , 2014, Journal of clinical lipidology.

[22]  Mark Woodward,et al.  Assessing Risk Prediction Models Using Individual Participant Data From Multiple Studies , 2013, American journal of epidemiology.

[23]  Mark Barnes,et al.  Preparing for responsible sharing of clinical trial data. , 2013, The New England journal of medicine.

[24]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[25]  S. Coady,et al.  Sharing individual level data from observational studies and clinical trials: a perspective from NHLBI , 2013, Trials.

[26]  J. Knowles,et al.  Role of international registries in enhancing the care of familial hypercholesterolaemia. , 2013, International journal of evidence-based healthcare.

[27]  J. Kastelein,et al.  Diagnosis and treatment of familial hypercholesterolaemia. , 2013, European heart journal.

[28]  G. Watts,et al.  Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. , 2012, The Journal of clinical endocrinology and metabolism.

[29]  J. Gallacher,et al.  Lipid-related markers and cardiovascular disease prediction. , 2012, JAMA.

[30]  Harlan M Krumholz,et al.  Open science and data sharing in clinical research: basing informed decisions on the totality of the evidence. , 2012, Circulation. Cardiovascular quality and outcomes.

[31]  S. Yamashita,et al.  Guidelines for the management of familial hypercholesterolemia. , 2012, Journal of atherosclerosis and thrombosis.

[32]  D. Rader,et al.  Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.

[33]  Vilmundur Gudnason,et al.  Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .

[34]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[35]  Stephen Kaptoge,et al.  Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies , 2010, International journal of epidemiology.

[36]  J. Kastelein,et al.  Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. , 2010, Atherosclerosis.

[37]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[38]  J. Witteman,et al.  Efficacy of statins in familial hypercholesterolaemia: a long term cohort study , 2008, BMJ : British Medical Journal.

[39]  Carolyn M Hutter,et al.  Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. , 2004, American journal of epidemiology.